Overview

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Status:
NOT_YET_RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the safety of avasopasem in combination with CDK 4/6 inhibitor and hormonal therapy in women with metastatic hormone receptor positive breast cancer, and to see if the addition of avasopasem improves the effectiveness of a CDK 4/6 inhibitor and hormonal therapy.

Phase:

PHASE1

Details

Lead Sponsor:

The University of Texas Health Science Center at San Antonio

Treatments:

avasopasem manganese